Extract to table

Production of non-public financial information must be handled with care to avoid any potential violation of applicable securities laws

Penterra's production of any document in response to any Request shall not be deemed an admission that such document is relevant, material, or admissible for any purpose, nor shall it be deemed an admission that the document supports or is consistent with any factual or legal position taken by Vantage

For purposes of these Responses and Objections, the following definitions shall apply: (a) "Agreement" or "EDA" means the Exclusive Distribution Agreement dated July 1, 2017, by and between Penterra Pharmaceuticals Corp

1 of the EDA, which provides that "[n]o amendment, modification, or supplement to this Agreement shall be effective unless made in writing and signed by duly authorized representatives of both Parties

1, which provides that no modification shall be effective unless in a signed writing

3 of the EDA provides: "Distributor shall not, directly or indirectly, market, sell, distribute, or promote the Products outside the Territory without the prior written consent of [Penterra]